Y-mAbs Therapeutics uses Alphalyse’s mAb characterization services to investigate batch differences of their mAbs. The results help them optimize their purification steps and are also useful for regulatory documentation.
Y-mAbs Therapeutics, Inc (Y-mAbs) is a late-stage clinical biopharmaceutical company that is listed on NASDAQ. The company devotes its energy to cancer treatment with antibody-based therapeutics. At the moment, they have two pivotal-stage product candidates – Naxitamab and Omburtamab.
Detailed mAb characterization service for optimization of purification steps
Y-mAbs needs protein analysis services on an ongoing basis. They use them to support the process development of new therapeutic products based on monoclonal antibodies. The services include mAb characterization.
After searching the market for possible lab partners, Y-mAbs entered into a close collaboration with Alphalyse. Here they get top-of-the-line LC-MS analyses including peptide mapping, intact mass determination and characterization of post translation modifications, such as disulfide bridges and glycosylations.
The results are used to compare various batches and for optimization of purification steps. Furthermore, it provides a basis for regulatory documentation.
If you would like to know more about our various mAb characterization service you can learn more on this page, dedicated to antibody analysis. You are of course also welcome to contact us to get advice specific to your project.